Health

What Hebei Can Offer丨Biomedicine and Beyond

SHIJIAZHUANG, China, Oct. 29, 2025 /PRNewswire/ -- A News Report from Great Wall New Media -- Among Hebei Province's 107 key specialized industrial clusters, the biopharmaceutical cluster in Shijiazhuang High-Tech Zone has emerged as a model of high-quality development and a key engine drivingHeb...

2025-10-29 15:23 1093

VUNO Partners with European Firms to Advance DeepCARS® Market Entry in Europe

- Strategic MOU enhances market access and extends reach to over 900 hospitals across the region SEOUL, South Korea, Oct. 28, 2025 /PRNewswire/ -- VUNO Inc., a global medical AI company, announced today that it has signed a strategic Memorandum of Understanding (MOU) with Contextflow, an Austria...

2025-10-29 09:14 1095

Charming Medical Limited Announces Full Exercise of Representative's Over-allotment Option

HONG KONG, Oct. 28, 2025 /PRNewswire/ -- Charming Medical Limited (Nasdaq: MCTA) (the "Company"), a Hong Kong-based provider of Traditional Chinese Medicine (TCM)-inspired therapies and products, today announced, in connection with its previously announced initial public offering (the "Offering")...

2025-10-29 04:15 2135

Tsingke Biotech Showcased AI-Powered Biomanufacturing Solutions at 2025 Festival of Biologics

BEIJING, Oct. 28, 2025 /PRNewswire/ -- Beijing Tsingke Biotech Co., Ltd. , a pioneer in molecular manufacturing, showcased its next-generation integrated platforms at the 2025Festival of Biologics in Basel. Over 2,000 biotech experts from 50 countries attended, witnessin...

2025-10-28 22:47 1016

Harbour BioMed Launches First Fully Human Generative AI HCAb Model to Accelerate Next-Generation Biologics Discovery

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Oct. 28, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced...

2025-10-28 22:07 1166

TCI Biotech to Showcase Leadership as the "Liquid Expert" at SupplySide Global 2025, Featuring Clinically-Proven Innovations for Weight Management and Metabolic Health

LAS VEGAS, Oct. 28, 2025 /PRNewswire/ -- TCI Biotech is staking its claim as the "Liquid Expert" of the wellness industry, a title it aims to cement at SupplySide Global 2025. Its core philosophy is that in a crowded wellness landscape, clinical validation and technological superiority, not just ...

2025-10-28 22:00 1149

Noul Supplies AI Diagnostic Platform miLab™ to Charité, Europe's Leading University Hospital

* Prestigious Nobel Prize–winning institution confirms adoption of miLab™ following clinical evaluation * "A milestone signaling broader adoption in advanced global healthcare markets" YONGIN, South Korea, Oct. 28, 2025 /PRNewswire/ -- Noul Co., Ltd.(CEO David Lim), an AI-driven blood and can...

2025-10-28 21:00 871

Fosun Pharma Announces 2025Q3 Financial Results

Innovative Achievements Continue to Come to Fruition, Revenue from Innovative Drugs ExceedingRMB6,700 Million in The First Three Quarters of 2025 SHANGHAI, Oct. 28, 2025 /PRNewswire/ -- On October 28, 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or "the Group"; SSE: 60019...

2025-10-28 20:11 1835

Myrio Therapeutics Announces Collaboration with Leading Research Institutions to Advance Solid Tumor T cell Immunotherapeutics

* Myrio Therapeutics, the University of Pennsylvania Perelman School of Medicine, and NYU Langone Health have entered a research collaboration to accelerate the development of next-generation T cell immunotherapies * Partnership with T cell experts Daniel J Powell Jr., PhD, and Mark Yarmarkov...

2025-10-28 19:35 782

WuXi AppTec Looks to Extend CRDMO Platform to Saudi Arabia as It Signs Strategic MoUs with NEOM and Ministry of Health

SHANGHAI, Oct. 28, 2025 /PRNewswire/ -- WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), today announced it has signed two strategic memoranda of understanding (MoUs) with NEOM, the sustainable region under development in northw...

2025-10-28 17:00 1469

Samsung Biologics reports third quarter 2025 financial results

* Recorded Q3'25 consolidated revenue of KRW 1,660.2 billion * Recorded Q3'25 consolidated operating profit of KRW 728.8 billion * Delivered consistent performance through stable capacity ramp-up and strengthened global partnerships INCHEON, South Korea, Oct. 28, 2025 /PRNewswire/ -- Samsung...

2025-10-28 14:50 1356

Fibronostics Acquires Stone Clinical Laboratories to Advance MASH/MASLD Diagnostics

Acquisition expands U.S. lab operations and accelerates innovation in non-invasive diagnostics for metabolic and liver diseases. NEW ORLEANS, Oct. 27, 2025 /PRNewswire/ -- Fibronostics, a global leader in non-invasive diagnostics for metabolic and liver diseases, today announced the completion o...

2025-10-27 22:46 1022

BioDlink Completes First International Shipment of Bevacizumab to Colombia

* Bevacizumab is a targeted therapy used to treat lung and colorectal cancers, both among the top three cancers ranked by death inColombia[1]. * This inaugural shipment—dispatched around two months after Colombia's marketing approval—demonstrates the company's efficiency, while validating its ...

2025-10-27 20:30 1023

National Center of Technology Innovation for Dairy Debuts at the IDF World Dairy Summit, Showcasing Innovation to Drive Sustainability

SANTIAGO, Chile, Oct. 27, 2025 /PRNewswire/ -- The highly anticipated 2025 IDF World Dairy Summit took place fromOctober 20 to 23 in Santiago, Chile. Drawing global attention, the event served as an important barometer for the future of the dairy industry. Liu Chunxi, Chairman of the National Ce...

2025-10-27 19:23 1147

Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunner

SYDNEY, Oct. 27, 2025 /PRNewswire/ -- Kazia Therapeutics Limited ("Kazia" or the "Company") today announced its intention to request and hold a follow-up Type C meeting with the U.S. Food & Drug Administration (FDA) to discuss overall survival (OS) findings in newly diagnosed glioblastoma (GBM) p...

2025-10-27 19:15 1823

Daewoong Pharmaceutical: Third IDMC Reaffirms Safety of Bersiporocin and Recommends Continuation of Global Phase 2 Clinical Trial

* Third Independent Data Monitoring Committee (IDMC) review confirms safety and continuation of the study * 94 patients enrolled out of 102 planned across Korea and the U.S.  * Interim baseline characteristics to be presented at the 2025 KATRD International Conference SEOUL, South Korea, Oct...

2025-10-27 19:00 1031

MINISH Technology Has Successfully Concluded Its First U.S. MINISH Veneers Course, Certifying 22 Dentists

SEOUL, South Korea, Oct. 27, 2025 /PRNewswire/ -- Health-tech company MINISH Technology Inc. announced on the 27th that 22 dentists completed its 15th MINISH Course, the first session held for local practitioners inthe United States.

2025-10-27 14:58 1025

Innovent's Mazdutide Shows Superiority in Glycemic Control with Weight Loss over Semaglutide in a Head-to-head Phase 3 Clinical Trial DREAMS-3

* The proportion of participants achieving HbA1c < 7.0% and a ≥10% reduction in body weight from baseline was 48.0% in the mazdutide group and 21.0% in the semaglutide group * DREAMS-3 is the world's first Phase 3 clinical trial of a GCG/GLP-1 dual receptor agonist to conduct a head-to-head c...

2025-10-27 08:00 1153

WuXi AppTec Achieves Strong Double-Digit Growth in Revenue and Profit for Q1-Q3 2025 Backlog for Continuing Operations Up 41.2% YoY Further Raises 2025 Full-year Guidance

* Q3 Total Revenue: RMB12.06 Billion, Up 15.3% YoY; * Revenue from Continuing Operations[1] Reached RMB12.04 Billion, Up 19.7% YoY * Q1-Q3 Total Revenue: RMB32.86 Billion, Up 18.6% YoY;  * Revenue from Continuing Operations Reached RMB32.45 Billion, Up 22.5% YoY * Q1-Q3 Net Profit Attributa...

2025-10-26 15:53 4280

Cardiovalve Completes TARGET Study Enrollment for CE Registration Study for Tricuspid Valve Replacement

The Company Advances Toward European CE Mark Submission with 150 Patients Enrolled; On Track for 2027 Commercial Launch HANGZHOU, China, Oct. 25, 2025 /PRNewswire/ -- Venus Medtech (Hangzhou) Inc. (2500.HK, hereinafter referred to as the "Company") today announced the successful completion of pa...

2025-10-25 15:00 2518
1 ... 10111213141516 ... 313